Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

589 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Encorafenib plus cetuximab treatment in BRAF V600E-mutated metastatic colorectal cancer patients pre-treated with an anti-EGFR: An AGEO-GONO case series.
Hafliger E, Boccaccino A, Lapeyre-Prost A, Perret A, Gallois C, Antista M, Pilla L, Lecomte T, Scartozzi M, Soularue E, Salvatore L, Bourgeois V, Salati M, Tougeron D, Evesque L, Vaillant JN, El-Khoury R, Lonardi S, Cremolini C, Taieb J. Hafliger E, et al. Among authors: lonardi s. Eur J Cancer. 2022 Jun;168:34-40. doi: 10.1016/j.ejca.2022.03.011. Epub 2022 Apr 15. Eur J Cancer. 2022. PMID: 35436675
Clinical impact of anti-epidermal growth factor receptor monoclonal antibodies in first-line treatment of metastatic colorectal cancer: meta-analytical estimation and implications for therapeutic strategies.
Loupakis F, Cremolini C, Salvatore L, Schirripa M, Lonardi S, Vaccaro V, Cuppone F, Giannarelli D, Zagonel V, Cognetti F, Tortora G, Falcone A, Bria E. Loupakis F, et al. Among authors: lonardi s. Cancer. 2012 Mar 15;118(6):1523-32. doi: 10.1002/cncr.26460. Epub 2011 Aug 25. Cancer. 2012. PMID: 22009364 Free article.
Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab.
Loupakis F, Cremolini C, Yang D, Salvatore L, Zhang W, Wakatsuki T, Bohanes P, Schirripa M, Benhaim L, Lonardi S, Antoniotti C, Aprile G, Graziano F, Ruzzo A, Lucchesi S, Ronzoni M, De Vita F, Tonini G, Falcone A, Lenz HJ. Loupakis F, et al. Among authors: lonardi s. PLoS One. 2013 Jul 4;8(7):e66774. doi: 10.1371/journal.pone.0066774. Print 2013. PLoS One. 2013. PMID: 23861747 Free PMC article.
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Taieb J, Tabernero J, Mini E, Subtil F, Folprecht G, Van Laethem JL, Thaler J, Bridgewater J, Petersen LN, Blons H, Collette L, Van Cutsem E, Rougier P, Salazar R, Bedenne L, Emile JF, Laurent-Puig P, Lepage C; PETACC-8 Study Investigators. Taieb J, et al. Lancet Oncol. 2014 Jul;15(8):862-73. doi: 10.1016/S1470-2045(14)70227-X. Epub 2014 Jun 11. Lancet Oncol. 2014. PMID: 24928083 Free article. Clinical Trial.
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Loupakis F, Cremolini C, Masi G, Lonardi S, Zagonel V, Salvatore L, Cortesi E, Tomasello G, Ronzoni M, Spadi R, Zaniboni A, Tonini G, Buonadonna A, Amoroso D, Chiara S, Carlomagno C, Boni C, Allegrini G, Boni L, Falcone A. Loupakis F, et al. Among authors: lonardi s. N Engl J Med. 2014 Oct 23;371(17):1609-18. doi: 10.1056/NEJMoa1403108. N Engl J Med. 2014. PMID: 25337750 Free article. Clinical Trial.
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.
Cremolini C, Loupakis F, Antoniotti C, Lupi C, Sensi E, Lonardi S, Mezi S, Tomasello G, Ronzoni M, Zaniboni A, Tonini G, Carlomagno C, Allegrini G, Chiara S, D'Amico M, Granetto C, Cazzaniga M, Boni L, Fontanini G, Falcone A. Cremolini C, et al. Among authors: lonardi s. Lancet Oncol. 2015 Oct;16(13):1306-15. doi: 10.1016/S1470-2045(15)00122-9. Epub 2015 Aug 31. Lancet Oncol. 2015. PMID: 26338525 Clinical Trial.
A new nomogram for estimating survival in patients with brain metastases secondary to colorectal cancer.
Pietrantonio F, Aprile G, Rimassa L, Franco P, Lonardi S, Cremolini C, Biondani P, Sbicego EL, Pasqualetti F, Tomasello G, Niger M, Casagrande M, Ghidini M, Muni R, Montrone S, Bergamo F, Berenato R, Fontanella C, Bozzarelli S, Moretto R, Battaglin F, Di Bartolomeo M, de Braud F, Miceli R. Pietrantonio F, et al. Among authors: lonardi s. Radiother Oncol. 2015 Nov;117(2):315-21. doi: 10.1016/j.radonc.2015.08.023. Epub 2015 Sep 4. Radiother Oncol. 2015. PMID: 26347495
Single-Agent Panitumumab in Frail Elderly Patients With Advanced RAS and BRAF Wild-Type Colorectal Cancer: Challenging Drug Label to Light Up New Hope.
Pietrantonio F, Cremolini C, Aprile G, Lonardi S, Orlandi A, Mennitto A, Berenato R, Antoniotti C, Casagrande M, Marsico V, Marmorino F, Cardellino GG, Bergamo F, Tomasello G, Formica V, Longarini R, Giommoni E, Caporale M, Di Bartolomeo M, Loupakis F, de Braud F. Pietrantonio F, et al. Among authors: lonardi s. Oncologist. 2015 Nov;20(11):1261-5. doi: 10.1634/theoncologist.2015-0171. Epub 2015 Oct 7. Oncologist. 2015. PMID: 26446234 Free PMC article.
Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer.
Moretto R, Cremolini C, Rossini D, Pietrantonio F, Battaglin F, Mennitto A, Bergamo F, Loupakis F, Marmorino F, Berenato R, Marsico VA, Caporale M, Antoniotti C, Masi G, Salvatore L, Borelli B, Fontanini G, Lonardi S, De Braud F, Falcone A. Moretto R, et al. Among authors: lonardi s. Oncologist. 2016 Aug;21(8):988-94. doi: 10.1634/theoncologist.2016-0084. Epub 2016 Jul 5. Oncologist. 2016. PMID: 27382031 Free PMC article.
589 results